XASEZOM
Market cap117mUSD
Dec 23, Last price
0.12USD
1D
-4.07%
1Q
-6.39%
IPO
-94.97%
Name
Zomedica Corp
Chart & Performance
P/E
—
P/S
4.68
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
60.01%
Rev. gr., 5y
%
Revenues
25m
+33.05%
Net income
-35m
L+102.93%
CFO
-16m
L+36.89%
Earnings
May 07, 2025
Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2016‑02 | 2015‑12 | 2015‑02 | |
| Income | |||||||||||
Revenues | 25,186 33.05% | 18,930 358.01% | 4,133 | ||||||||
Cost of revenue | 56,778 | 40,669 | 2,752 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (31,592) | (21,739) | 1,381 | ||||||||
NOPBT Margin | 33.41% | ||||||||||
Operating Taxes | (1,331) | (2,366) | (2,333) | ||||||||
Tax Rate | |||||||||||
NOPAT | (30,261) | (19,373) | 3,714 | ||||||||
Net income | (34,529) 102.93% | (17,015) -7.44% | (18,383) 8.64% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 215,622 | ||||||||||
BB yield | -73.55% | ||||||||||
| Debt | |||||||||||
Debt current | 1,832 | 1,282 | 415 | ||||||||
Long-term debt | 4,544 | 2,835 | 2,343 | ||||||||
Deferred revenue | 252 | 182 | 140 | ||||||||
Other long-term liabilities | 944 | 1,883 | 361 | ||||||||
Net debt | (94,126) | (151,687) | (192,194) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (15,975) | (11,670) | (14,275) | ||||||||
CAPEX | (4,646) | (1,026) | (526) | ||||||||
Cash from investing activities | 1,577 | (155,880) | (71,925) | ||||||||
Cash from financing activities | 8 | 219,159 | |||||||||
FCF | (47,034) | (27,004) | 1,560 | ||||||||
| Balance | |||||||||||
Cash | 90,497 | 115,092 | 194,952 | ||||||||
Long term investments | 10,005 | 40,712 | |||||||||
Excess cash | 99,243 | 154,858 | 194,746 | ||||||||
Stockholders' equity | 210,088 | 243,726 | 261,572 | ||||||||
Invested Capital | 146,532 | 117,432 | 77,780 | ||||||||
ROIC | 7.87% | ||||||||||
ROCE | 0.50% | ||||||||||
| EV | |||||||||||
Common stock shares outstanding | 979,950 | 979,924 | 956,534 | ||||||||
Price | 0.20 22.82% | 0.16 -46.82% | 0.31 32.91% | ||||||||
Market cap | 196,186 22.83% | 159,728 -45.52% | 293,178 248.85% | ||||||||
EV | 102,060 | 8,041 | 100,983 | ||||||||
EBITDA | (25,294) | (17,697) | 2,521 | ||||||||
EV/EBITDA | 40.06 | ||||||||||
Interest | 175 | 1,000 | 6 | ||||||||
Interest/NOPBT | 0.44% | ||||||||||